Who are Cellcept's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycophenolate, Mycophenolate, XR-tacrolimus QD + MMF BID then MMF QD, LCP-tacrolimus QD + MMF QD then MMF QD, XR-tacrolimus QD + MMF BID.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mycophenolate-mofetil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Cellcept — Competitive Intelligence Brief

Cellcept (MYCOPHENOLATE MOFETIL) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite Immunosuppressant. Area: Oncology.

marketed Antimetabolite Immunosuppressant Inosine-5'-monophosphate dehydrogenase 2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cellcept (MYCOPHENOLATE MOFETIL) — Roche Palo. Cellcept works by inhibiting the enzyme inosine-5'-monophosphate dehydrogenase 2, which is necessary for the production of guanosine nucleotides.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cellcept TARGET	MYCOPHENOLATE MOFETIL	Roche Palo	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	1995-01-01
Mycophenolate	MYCOPHENOLIC ACID	Novartis	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	2004-01-01
Mycophenolate	Mycophenolate	Sanofi	marketed		Inosine-5'-monophosphate dehydrogenase 1, Inosine-5'-monophosphate dehydrogenase 2, Inosine-5'-monophosphate dehydrogenase (IMPDH)
XR-tacrolimus QD + MMF BID then MMF QD	XR-tacrolimus QD + MMF BID then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); Inosine monophosphate dehydrogenase (mycophenolate mofetil)
LCP-tacrolimus QD + MMF QD then MMF QD	LCP-tacrolimus QD + MMF QD then MMF QD	University Hospital, Limoges	marketed	Calcineurin inhibitor + antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); inosine monophosphate dehydrogenase type II (MMF)
XR-tacrolimus QD + MMF BID	XR-tacrolimus QD + MMF BID	University Hospital, Limoges	marketed	Calcineurin inhibitor + Antimetabolite immunosuppressant combination	Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2039-08-16 — Cellcept · 12194143 · Formulation · US
2039-08-16 — Cellcept · 12097285 · Formulation · US
2039-08-16 — Cellcept · 12226526 · Formulation · US
2039-08-16 — Cellcept · 11931455 · Formulation · US
2039-08-16 — Cellcept · 12097284 · Formulation · US

Sponsor landscape (Antimetabolite Immunosuppressant class)

Novartis · 1 drug in this class
Roche Palo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cellcept — Competitive Intelligence Brief. https://druglandscape.com/ci/mycophenolate-mofetil. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab